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Mucosal tissues serve as major sites of entry, rep-
lication, and exit for many pathogens. Indeed, 
herpesviruses often persist in and are shed from 
mucosal tissues for long periods of time despite 
strong adaptive immune responses in their host. 
Understanding how pathogens persist in muco-
sal tissue may assist the design of eff  ective vacci-
nation and immunotherapeutic strategies.
Human CMV (HCMV) is a β-herpesvirus 
that infects the majority of the world’s popula-
tion. Although this persistent/latent infection 
is asymptomatic in healthy individuals, HCMV 
causes multiorgan disease in the immunologi-
cally immature (e.g., congenital infection) and 
the immune-compromised population (e.g., 
AIDS patients and organ transplant recipients). 
Asymptomatic shedding in saliva is an impor-
tant source of virus in natural transmission of 
HCMV (1–3), implying that virus replication 
in the salivary glands is pivotal for horizontal 
transmission. After systemic infection, mouse 
CMV (MCMV) initially replicates in visceral 
organs such as the spleen and liver, but virus 
production is limited by NK cell and adaptive 
cellular immunity within a week after infection. 
Despite strong cellular immunity, infectious vi-
rus is produced in the acinar glandular epithe-
lial cells within the submaxillary salivary glands 
(4) and can be detected for several months after 
primary infection (4–6). Like all herpesvirus, 
MCMV establishes latency (5, 7), yet very little 
is known about how CMV persists within the 
salivary glands. CD4 T cells producing IFN-γ 
have been described to aff  ord protection at this 
site (5, 8), but it is not clear if or how these cells 
are regulated. CMV can inhibit CD4 T cell 
  activation by interfering with IFN-γ–induced 
MHC class II expression (9). Viral genes that 
interfere with antigen presentation to CD8 T 
cells infl  uence virus replication in the salivary 
glands, suggesting mucosal CD8 T responses are 
also targeted (10). In BALB/c mice, NK cells 
and γδ T cells have also been detected within 
the salivary glands after MCMV infection (11), 
but their role in clearance is not known. As a 
target of persistent infection, the salivary glands 
are exposed to substantial antigenic burden 
without obvious pathology. Thus, it is likely 
that infl  ammatory immune cells at this site may 
be regulated diff  erently than in other tissues. 
Potential mechanisms could include induc-
tion of T cell anergy or apoptosis (12). Immune 
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responses may also be actively suppressed by regulatory T 
cells, such as naturally occurring CD4+CD25+ T regulatory 
(T reg) or T reg cells induced by antigen, which are defi  ned 
by the expression of suppressive cytokines, including IL-10 
or TGF-β (13, 14).
We now report that cellular immunity in the salivary 
glands to a persistent virus is regulated through an IL-10–
dependent mechanism. We observed that persistent MCMV 
replication in the salivary glands was accompanied by the ap-
pearance of IL-10–expressing CD4 T cells specifi  cally within 
this organ, but not elsewhere. Blockade of IL-10R signaling 
during infection dramatically decreased virus replication that 
correlated with increased accumulation of CD4 T cells ex-
pressing antiviral IFN-γ. Further, targeting CD4 T cell dif-
ferentiation through activation of the TNFR family member 
OX40 (15) increased the ratio of CD4 T cells expressing 
IFN-γ compared with IL-10 in the salivary glands and re-
duced persistent replication of MCMV. Collectively, these 
data show that MCMV exploits the salivary gland environ-
ment favoring IL-10 expression by virus-induced CD4 T cells, 
thus enabling persistent virus replication and horizontal trans-
mission to susceptible hosts.
Figure 1.  IL-10–expressing CD4 T cells accumulate in the salivary 
glands during persistent MCMV infection. (A) 14 d after MCMV 
infection of mice, accumulation of CD4+CD3+, CD8+CD3+, B220+, 
NK+CD3−, F4/80+, and CD11c+ cells (A) were measured. (B and C) After 
5 h with (white bars) or without (black bars) stimulation with anti-CD3/
anti-CD28, IFN-γ (B), and IL-10 (C) expression by CD4+TCRβ+ and 
CD8+TCRβ+ cells and TCR-β− cells derived from the salivary glands was 
measured. (D) IL-10 expression in salivary gland extracts from naive and 
MCMV-infected mice 14 d after infection was measured by quantitative 
PCR and was normalized to 18S RNA. *, P < 0.05, with student’s t test. 
All results are expressed as mean ± SD of three to four mice per group. 
(E) IL-10 expression by TCR-β+ cells in the salivary glands, draining 
lymph nodes, and spleen was analyzed by intracellular stain 5 h after 
stimulation with anti-CD3/anti-CD28 (top). Data are representative 
plots (n = 4) staining for CD4 versus IL-10 or isotype control on gated 
live lymphocytes. (bottom) Expression of IL-4, IL-5, IL-13, and FoxP3 
(unshaded lines) compared with isotype control (shaded lines) by gated 
CD4+IL-10+ cells visualized 5 h after in vitro stimulation of salivary 
gland leukocytes 14 d after infection. Positive control for FoxP3 staining 
(dashed line) is CD4 T cells derived from spleens of naive mice. (F) On 0, 
7, 14, and 30 d after infection, the number of CD4+IL-10+ cells (○) 
and virus titers (●) in the salivary glands were measured. Results are 
expressed as mean ± SD of four mice per group, and all results are rep-
resentative of three experiments.JEM VOL. 204, May 14, 2007  1219
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RESULTS
IL-10–expressing CD4 T cells accumulate in the salivary 
glands as MCMV replicates
MCMV replication can be detected for 1–2 mo in the sub-
maxillary salivary glands, but not in the spleen, after a primary 
infection in C57BL/6 (B6) mice (6). Persistent MCMV rep-
lication in the salivary glands induced the accumulation of 
CD4 and CD8 T cells, B cells, NK cells, and antigen-pre-
senting cells (Fig. 1 A). Cytokine expression analysis of sali-
vary gland–derived leukocytes revealed that T cells (primarily 
CD4 T cells) were the predominant source of low spontane-
ous expression of antiviral cytokine IFN-γ, which was am-
plifi  ed by ex vivo polyclonal stimulation (Fig. 1 B).
Interestingly, we observed a considerable accumulation in 
the salivary glands of CD4 T cells expressing the immuno-
suppressive cytokine IL-10 during persistent MCMV replica-
tion, although these cells were not detected in visceral sites 
such as the spleen or in the lymph nodes draining the salivary 
glands (Fig. 1, C and E). We found a low percentage of CD4 
T cells making detectable IL-10 (0.5–1%) without ex vivo 
restimulation (Fig. 1 C), suggesting that the results derived 
from stimulation with CD3/CD28 represented an ampli-
fi  cation of cytokine production by these cells. Further rein-
forcing the notion that this IL-10 production refl  ected  a 
physiological event in vivo, we found strong expression of 
IL-10 in salivary gland extracts from infected but not naive 
mice (Fig. 1 D). Importantly, CD8 T cells and non–T cells 
did not express notable levels of IL-10, suggesting CD4 
T cells were the predominant source of this cytokine (Fig. 1 C). 
IL-10–producing CD4 T cells did not co-express IL-4, IL-5, 
Figure 2.  OX40 activation inhibits virus replication and enhances 
cellular infi  ltration in the salivary glands during MCMV infection. 
(A) OX40 expression by salivary gland–derived CD4+CD3+ (left) and 
CD8+CD3+ (right) cells 14 d after MCMV infection (unshaded line) com-
pared with isotype-stained control (shaded line). (B) The percentage of 
OX40-expressing CD4+CD3+ T cells isolated from the salivary glands (●) 
and draining lymph nodes (○) 0, 7, 14, and 30 d after infection. (C) MCMV-
infected mice were treated with IgG (black bars) or anti-OX40 (white 
bars), and after 7 and 30 d salivary glands were assayed for infectious 
virus (C). (D) Hematoxylin and eosin–stained salivary gland sections 14 d 
after infection from control Ig (left) and anti-OX40– (right) treated mice. 
Acinus (large black arrowhead), duct (white arrowhead), and glandular 
epithelial cells with an intranuclear inclusion indicative of virus cyto-
pathic effect (small black arrowhead) are shown in the section from 
Ig-treated mice. Bars, 200 μm. (E) Numbers of CD4 T cells in the salivary 
glands of IgG (■) and anti-OX40– (□) treated mice 0, 7, 14, and 30 d 
after infection. (F) Wild-type C57BL/6 and MHCII−/− mice were infected 
with MCMV and treated with IgG (black bars) or anti-OX40 (white bars), 
and 30 d later salivary glands were assayed for infectious virus. Data pre-
sented in B, C, E, and F represent mean ± SD of four mice per group, 
and all data is representative of three to fi  ve independent experiments. 
*, P < 0.05, with student’s t test.1220  IL-10 AND OX40 COUNTERREGULATE ANTIVIRAL T CELLS | Humphreys et al.
IL-13, or FoxP3, implying these cells were not conventional 
T helper (Th)2 cells or naturally occurring T reg cells (Fig. 1 E). 
Moreover, the accumulation of IL-10–expressing CD4 
T cells accompanied MCMV replication in the salivary glands 
(Fig. 1 F), demonstrating these T cells were actively induced 
by the virus infection.
OX40 induces IFN-𝗄 expression and limits persistent 
MCMV replication
IFN-γ–expressing CD4 T cells inhibit MCMV replication 
in the salivary glands (8). Although CD4+IFN-γ+ T cells 
were present (Fig. 1 B), the results suggested that IL-10–
secreting cells might limit either antiviral activity of IFN-γ+ 
T cells or the IFN-γ itself. We hypothesized that shifting 
the ratio of CD4 T cells to favor IFN-γ production might 
limit virus replication. To accomplish this, we targeted the 
TNFR OX40 with an agonist antibody based on the abil-
ity of this receptor to enhance IFN-γ secretion (16, 17) and 
suppress IL-10 production by T cells (18, 19). OX40 was 
detected on CD4 but not CD8 T cells infi  ltrating the in-
fected salivary glands (Fig. 2, A and B) and in draining lymph 
nodes (Fig. 2 B), indicating that ectopic targeting of OX40 
with an agonist antibody was feasible. Mice treated with an 
agonist anti-OX40 antibody at the time of infection had no 
discernable eff  ect on early (day 7 after infection) viral load in 
the salivary glands (Fig. 2 C). However, anti-OX40–treated 
mice had substantially reduced titers of replicating virus at 
30 d after infection (Fig. 2 C). This was associated with 
  increased infi  ltration of mononuclear cells compared with 
control mice (Fig. 2 D). Further analysis revealed that this 
cellular infi  ltrate consisted primarily of CD4 T cells (Fig. 2 E), 
and we found that the elevated CD4 response was critical 
for OX40-mediated inhibition of MCMV-persistent repli-
cation, as the protective eff  ect was abolished in MHC class 
II–defi  cient mice (Fig. 2 F). In contrast, OX40 stimulation 
did not alter the accumulation of total or MCMV-specifi  c 
CD8 T cells, or granzyme B–expressing CD8 T cells in the 
salivary glands (Fig. S1, A–C, available at http://www.jem
.org/cgi/content/full/jem.20062424/DC1).
OX40 activation increased the percentage (Fig. 3, A and B) 
and total numbers (unpublished data) of CD4 T cells, but not 
CD8 T cells (Fig. S1 D), expressing IFN-γ. Moreover, anti-
OX40 treatment also reduced the percentage of IL-10–
  expressing CD4 T cells (Fig. 3, C and D), altering the ratio of 
T cells expressing IFN-γ to IL-10 in the salivary glands (Fig. 
3 E). This eff  ect of OX40 activation was also refl  ected in a 
shift in the expression of IFN-γ and IL-10 in situ (Fig. 3 F). 
These data show that virus replication in the salivary glands is 
reduced when OX40 is activated, which is associated with an 
increased ratio of IFN-γ to IL-10–expressing CD4 T cells.
Blockade of IL-10R limits MCMV replication 
in the salivary glands
To determine whether the restricted virus replication and 
the increased ratio of IFN-γ to IL-10–secreting CD4 T cells 
  involved IL-10, we used an antagonist IL-10R antibody 
(anti–IL-10R) to block signaling. Administration of this antibody 
enhanced the accumulation of total and IFN-γ–expressing 
CD4 T cells in the salivary glands (Fig. 4, A and B), but had 
no eff  ect on the accumulation of CD8+ T cells or NK+CD3− 
cells expressing IFN-γ (Fig. S2 A, available at http://www
.jem.org/cgi/content/full/jem.20062424/DC1). The accu-
mulation of CD4+IL-10+ T cells was not a result of IL-10R 
signaling in this organ (Fig. 4, C and D). Importantly, virus 
replication was dramatically inhibited by blocking IL-10R, 
with no virus detectable in two treated mice (n = 3) after 30 d 
of infection (Fig. 5 A). Moreover, when anti–IL-10R treat-
ment was started at 7 d after infection to coincide with the 
appearance of IL-10+ cells (Fig. 1 E), virus levels in salivary 
glands remained undetectable in fi  ve out of eight mice (Fig. 5 B). 
Figure 3.  OX40 activation alters the ratio of IFN-𝗄 to IL-10–
expressing cells in the salivary glands during MCMV infection. 
B6 mice were infected with MCMV and treated with rat IgG or anti-OX40 
at the time of infection. IFN-γ and IL-10 expression was measured in 
salivary gland–derived CD4 T cells from IgG and anti-OX40–treated mice 
at various times after MCMV infection, after ex vivo stimulation with anti-
CD3 and anti-CD28. (A and C) Representative plots of IFN-γ (A) and 
IL-10 (C) expression by CD4 T cells from Ig (left) or anti-OX40– (right) 
treated mice 14 d after infection. (B and D) The percentage of CD4+ 
T cells expressing IFN-γ (B) or IL-10 (D) in the salivary glands of Ig 
and anti-OX40–treated mice over time. (E) Ratio of IFN-γ to IL-10–
  producing CD4 cells, calculated as the ratio of the percentages of IFN-γ–
expressing CD4 cells to IL-10–expressing CD4 cells. All results are 
expressed as mean ± SD of four to seven mice per group over a 30-d 
time-course infection. (F) IFN-γ and IL-10 expression in salivary gland 
extracts measured by quantitative PCR and normalized to 18S RNA. 
Data are presented as a ratio of IFN-γ to IL-10 expression per mouse. 
All results represent two to three experiments. *, P < 0.05, with 
student’s t test.JEM VOL. 204, May 14, 2007  1221
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Collectively, these data highlight the salivary glands as sites of 
strong IL-10–dependent immune regulation and demonstrate 
that IL-10–producing CD4 T cells suppress antiviral eff  ector 
CD4 T cells. The results demonstrate that modulation of the 
OX40 and IL-10 pathways can block virus replication in this 
important excretory organ.
DISCUSSION
The salivary glands are a site of IL-10–dependent immune 
regulation. We demonstrated that IL-10–producing CD4 
T cells suppressed eff  ector CD4 T cells in a model of persis-
tent virus replication at this mucosal site. The results establish 
that the IL-10 immunoregulatory pathway enables MCMV 
to persistently replicate in this mucosal organ. Counteracting 
this viral strategy by modulation of either the costimulatory 
OX40 pathway with an agonist antibody or targeting the im-
munoregulatory IL-10 pathway with an antagonist antibody, 
limited persistent virus replication in the salivary glands, at-
tenuating shedding of virus, thus potentially reducing trans-
mission to susceptible hosts.
Sustained activation of the TNFR OX40 with an agonist 
antibody favored the diff  erentiation and accumulation of CD4 
T cells that produced IFN-γ in the salivary glands to coun-
teract the inhibitory eff  ects of the IL-10–dominated immune 
response. OX40 was expressed on antigen-activated CD4 
T cells, which were readily detected in the spleen, salivary 
glands, and draining lymph nodes from MCMV-infected 
mice. T cells express OX40 for short periods of time after 
antigen activation; thus, virus reactive T cells were the mostly 
likely targets of the antibody, and therefore, treatment subse-
quently altered virus-specifi  c cytokine expression. Activation 
of OX40 can favor generation of eff  ector Th1 or Th2 cells 
(16, 17, 20, 21), which are distinguished by their expression 
of IFN-γ or IL-4, IL-5, and IL-13, respectively. OX40 stim-
ulation during MCMV infection enhanced the accumulation 
of CD4 T cells coexpressing IFN-γ and the activation-asso-
ciated isoform of CD43 (unpublished data), suggesting that 
OX40 signaling directly impacted the diff  erentiation of anti-
viral Th1 primary eff  ector cells.
CD4 T cells in the salivary glands were identifi  ed as the 
predominant source of IL-10, representing  80–90% of all 
IL-10–expressing cells. In contrast to peripheral chronic are-
navirus infection (22, 23), MCMV replication in the salivary 
glands did not induce expression of IL-10 by CD11c+ den-
dritic cells (unpublished data). IL-10–expressing CD4 T cells 
did not co-express the Th2-associated cytokines IL-4, IL-5, 
or IL-13, nor did they express the transcription factor FoxP3, 
which is a marker of naturally occurring CD4+CD25+ 
T reg cells. Collectively, the data indicated these T cells were 
IL-10– producing T reg cells, which have been described to 
mediate peripheral tolerance (24, 25) and suppresses mucosal 
infl   ammation in the gut (26). Interestingly, recent studies 
have reported that conventional Th1 cells can express IL-10 
during chronic parasitic infections (27, 28). Whether MCMV-
induced IL-10–expressing CD4 T cells represent T reg  ulatory 
1 or Th1 cells, or a combination of both, is currently unknown. 
Regardless of the exact lineage of these cells, however, this cur-
rent study is the fi  rst description of a role for IL-10– expressing 
CD4 T cells in the salivary glands.
IL-10 suppresses infl  ammatory immune responses by in-
hibiting the expression of proinfl  ammatory cytokines and 
chemokines, and decreasing expression of MHC class II 
and costimulatory molecules by APC, which subsequently 
limits differentiation or expansion of CD4 T cell effec-
tor re  sponses (29). The dramatic reduction in persistent virus 
Figure 4.  IL-10R blockade augments accumulation of IFN-𝗄–
producing CD4 T cells in the salivary glands. C57BL/6 mice were in-
fected with MCMV and treated with rat IgG or anti–IL-10R on days 0 
and 7 after infection. Total CD4 T cells (A) and IFN-γ (A) and IL-10– (C) 
expressing CD4 T cells in the salivary glands of IgG (black bars) and anti–
IL-10R– (white bars) treated mice were quantifi  ed 14 d after infection. 
Results are expressed as mean ± SD from three to four mice per group. 
*, P < 0.05, with student’s t test. (B and D) Representative FACS plots of 
CD4 versus IFN-γ (B) or IL-10 (D). Quadrants were set using isotype con-
trol antibodies, and results represent four mice per group. All results are 
representative of three similar experiments.
Figure 5.  Blockade of IL-10R signaling inhibits MCMV persistence. 
MCMV-infected mice were treated with IgG (●) or anti–IL-10R on days 
0 and 7 (A) or 7 and 14 (B) after infection. After 30 d, salivary glands were 
assayed for infectious virus. Individual mice plus mean are shown. Re-
sults are representative of three similar experiments. Undetectable titers 
are expressed as an arbitrary value of 1 for display on a logarithmic scale.1222  IL-10 AND OX40 COUNTERREGULATE ANTIVIRAL T CELLS | Humphreys et al.
replication after IL-10R blockade was associated with increased 
IFN-γ–producing Th1 cells in the salivary glands, implying 
that IL-10 might act directly on eff  ector T cells in the local 
microenvironment. Alternatively, IL-10 may suppress T cells 
indirectly by down-regulating one or more functions asso-
ciated with APC. A previous study showed that MCMV-
induced IL-10 in APC suppressed MHC class II expression by 
macrophages in vitro (30). However, we observed no change 
in MHC class II expression by cells infi  ltrating the salivary 
glands after IL-10R blockade (Fig. S2, B and C), suggest-
ing this explanation cannot account for the action of IL-10 
in vivo. The strong eff  ect of anti-OX40 treatment in promot-
ing IFN-γ–secreting CD4 T cell accumulation in the salivary 
glands suggests that IL-10 may predominantly act to suppress 
expression of costimulatory ligands such as OX40L and/or 
production of antiviral cytokines by APC, either in the sali-
vary glands, or in the case of dendritic cells, after migration 
to draining lymph nodes.
In this mouse model of persistent virus replication, we have 
identifi  ed two distinct approaches to counteracting   immune 
regulation. Regardless of the mechanism of IL-10–mediated 
suppression, the effi   cacy of IL-10R blockade in preventing 
  viral replication was remarkable. Furthermore, delaying treat-
ment until a week after infection, after CD4 and CD8 primary 
responses were established, dramatically altered virus replica-
tion in the salivary glands, showing the importance of IL-10 
during this late stage of the antiviral response.
Targeting OX40 was also effi   cacious perhaps because of 
the expression of OX40 on antigen-reactive T cells, altering 
cytokine expression. This conclusion is guarded because 
MCMV peptides presented by class II MHC have not yet 
been defi  ned to directly visualize antigen-specifi  c T cells. The 
blockade of persistent viral replication by OX40 activation 
was associated with the accumulation of IFN-γ–secreting 
CD4 T cells previously described to aff  ord protection from 
MCMV replication in the salivary glands (5, 8). Furthermore, 
the protective eff  ect of OX40 stimulation was accompanied 
by a strong alteration in the ratio of IFN-γ to IL-10–ex-
pressing CD4 T cells. In a tissue culture model, the presence 
of OX40L on dendritic cells inhibited IL-10 expression in 
human CD4 T cells diff  erentiating under both Th1 and Th2 
priming conditions (19), suggesting that OX40 may directly 
antagonize IL-10 expression. However, the transcription fac-
tor GATA-3, which is implicated in the transcriptional con-
trol of IL-10 expression (31), can also be induced by OX40 
stimulation in an IL-4R–dependent manner (21). This latter 
result suggests that, in certain conditions, OX40 could en-
hance IL-10 expression. Indeed, although we found an al-
tered ratio of IFN-γ to IL-10–expressing T cells after OX40 
stimulation, the actual numbers of IL-10–producing CD4 
T cells did not change signifi  cantly. Furthermore, the level of 
IL-10 expression by CD4+IL-10+ T cells, as indicated by 
mean fl  uorescent intensity, was also unaltered by OX40 stim-
ulation (unpublished data). Thus, the action of OX40 
most likely refl  ected a preferential increase of Th1 eff  ector 
cell diff  erentiation and/or accumulation of Th1 cells in the 
salivary glands independent of IL-10. This conclusion is con-
sistent with data where OX40 was shown to promote Th1 
cell accumulation at the site of infection with infl  uenza 
(32, 33) and Cryptococcus neoformans (20). Moreover, OX40 
signaling can directly induce IFN-γ secretion and promote 
Th1 diff  erentiation in tissue culture (16, 17). Anti-OX40 
treatment reduced the viral load in the salivary glands by 1–2 
log10, whereas anti–IL-10R reduced titers by 3 log10. The 
diff  erence between the two pathways may refl  ect the fi  nding 
that the IL-10–expressing CD4 T cells were not eliminated 
by treatment with anti-OX40. The fi  nding that neither treat-
ment altered the numbers of CD4+IL-10+ T cells indicates 
the diff  erence in effi   cacy in reducing virus replication repre-
sented a fundamental distinction between the OX40 and 
IL-10R signaling pathways.
The ratio of T cells expressing IFN-γ to IL-10 provides a 
useful marker of immune regulation in the salivary glands and 
perhaps at other mucosal sites. A shift to IFN-γ expression 
pattern is critical for eff  ective clearance of chronic parasitic 
infections (34), and correspondingly IFN-γ is necessary for 
the control of chronic MCMV infection (35). Elevated IFN-γ 
expression in the salivary glands may reduce viral persistence 
by directly inhibiting virus replication (35–37) or activation 
of additional eff  ector mechanisms, such as NK, γδ T cells, 
and macrophages in the salivary glands (11, 38–40). IFN-γ 
also promotes CD8 T cell responses; however, in the con-
text of the salivary glands, CD8 T cells do not limit virus 
replication (5), and neither anti-OX40 nor anti–IL-10R 
treatment had any eff  ect on virus-specifi  c CD8 T cell num-
bers, IFN-γ expression, or granzyme B expression, suggest-
ing a minimal role for CD8 T cells in the protective eff  ect 
of either treatment.
Induction of CD4+IL-10+ T cells after MCMV infection 
may represent a mucosal tolerance mechanism used by the 
salivary glands that is exploited by MCMV. It is likely that 
MCMV takes an active role in the exploitation of the mucosal 
tissue. Interestingly, MCMV alters the microarchitecture 
of the spleen by selective depression of CCL21 chemokine 
mRNA expression, which alters T cell traffi   cking within the 
spleen (41). Mutations in the viral genes M155 (42), M35 
(43), or M133 (44, 45) abrogate replication in the salivary 
glands, although the role of these genes in promoting IL-10–
expressing T cells is not understood. Of signifi  cance is the 
presence of viral IL-10 orthologs in primate CMV (46, 47), 
Epstein-Barr virus (48), and equine herpesvirus 2 (49). Al-
though MCMV does not encode an obvious IL-10 ortholog, 
the observation that MCMV utilizes an IL-10–dependent 
mechanism to persist in salivary glands suggests a strong selec-
tive pressure is driving the conservation of targeting the 
IL-10 pathway in herpesviridae. The results raise the intriguing 
possibility that the primary function of cmvIL-10 in vivo 
may be to mimic IL-10–expressing T reg cells to block the 
action of the eff  ector T cells secreting IFN-γ, allowing 
persistent virus replication specifi  cally at mucosal sites. Thus, 
viral IL-10 orthologs may represent important targets to 
limit persistent virus replication in mucosal tissues such as the JEM VOL. 204, May 14, 2007  1223
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  salivary glands, which in turn may block transmission of virus 
to new hosts.
MATERIALS AND METHODS
Mice. Wild-type female C57BL/6 (B6) mice were purchased from The 
Jackson Laboratory, and MHC class II–defi  cient mice (50) were purchased 
from Taconic. All experiments were approved by institutional Animal Care 
and Use Committee.
Virus infections and antibody treatment
MCMV Smith (American Type Culture Collection) was prepared and 
  titered as described previously (51). Mice were infected with 5 × 104 pfu 
MCMV by intraperitoneal route and, in some experiments, injected i.p. at 
the time of infection with 100 μg of either rat IgG (Chemicon) or anti-
OX40 (clone OX86 [52]) purifi  ed by protein A affi   nity chromatography. In 
other experiments, mice were injected i.p. with 250 μg rat IgG1κ (clone 
R3-34; BD Biosciences) or anti-CD210 (anti–IL-10Rα clone 1B1.3a; BD 
Biosciences [53]).
Leukocyte isolation, intracellular cytokine staining, 
and fl  ow cytometry
Salivary glands were surgically excised and tissue leukocytes were isolated as 
previously described (11). In brief, salivary glands, free of associated lymph 
nodes, were cut into small pieces and incubated in RPMI 1640 supple-
mented with 5 mM CaCl2, 5% fetal bovine serum, 1 mg/ml collagenase D 
(Roche Diagnostics), and 10 μg/ml DNase I (USB) at 37°C with mild agitation. 
After two consecutive incubations, dissociated cells and salivary gland tissue 
was passed through a 40-μm nylon cell strainer, and extruded cells were 
washed with PBS before analysis. The draining lymph nodes of the salivary 
glands were also excised, and cells were isolated by passage through a 40-μm 
nylon cell strainer.
Isolated leucocytes were then incubated at 5 × 106 cells/ml for 5 h at 
37°C in the presence of 2 μg/ml brefeldin A (Sigma-Aldrich) and stimulated 
with or without 1 μg/ml anti-CD3 (clone 145–2C11) and 1 μg/ml anti-
CD28 (clone 37.51; BD Biosciences), or 2 μg/ml of MCMV-derived pep-
tides (Genemed Synthesis Inc.). The peptides used were the H-2Db–restricted 
M45-derived peptide HGIRNASFI and the H-2Kb–restricted peptides de-
rived from the M38 (SSPPMFRVP), M57 (SCLEFWQRV), and M139 
(TVYGFCLL) open reading frames, as previously described (54). Cells were 
then washed and incubated with Fc receptor blocking reagent and then 
stained with anti–CD8-PE-Cy7, anti–TCRβ-PE-cy5, and anti-CD4 anti-
body conjugated to FITC or APC-cy7 (BD Biosciences). Cells were then 
fi  xed with 4% formalin and permeabilized with saponin buff  er (PBS, 2% 
FBS, 0.05% sodium azide, and 0.5% saponin) and stained with anti–IFN-γ-
FITC or PE and, in some experiments, anti–IL-10-APC and PE-labeled 
anti–IL-5, anti–IL4, anti-FoxP3, or anti–IL-13 biotin (R&D Systems) fol-
lowed by streptavidin-PE (BD Biosciences). In some experiments, un-
stimulated cells treated with brefeldin A were stained with anti-CD8 and 
anti–human granzyme B–PE (Catag/Invitrogen Life Technologies) or 
anti–NK1.1-APC and anti–IFN-γ. In other experiments, splenocytes were 
immediately stained with anti–MHC class II, anti-B220, anti-CD11c, anti–CD8-
PE-cy7, anti–CD4-APC-cy7 (BD Biosciences), anti-F4/80 (eBioscience), 
and/or OX40-PE (Serotec). All cells were acquired on an LSR II fl  ow 
  cytometer (BD Bioscience).
Histology
Salivary glands were fi  xed in 10% formalin, paraffi   n-embedded, and 5-μm 
sections were stained with hematoxylin and eosin. Three sections from each 
gland were examined from four mice per group.
Gene expression
IFN-γ and IL-10 mRNA were assayed by quantitative RT-PCR using Strat-
agene Mx 4000 and SYBR green reagent (Bio-Rad Laboratories). Salivary 
glands from mock or MCMV-infected mice were snap frozen in liquid nitro-
gen before homogenization in TRIzol reagent (Invitrogen Life Technologies). 
Total cellular RNA was then isolated and quantifi  ed before performing 
DNase digestion and reverse transcription as described (55). The primer se-
quences for detection of mouse IFN-γ are GCCGTGGCAGTAACAGCC 
and AACGCTACACACTGCATCTGGG, and for IL-10 are CACTGC-
TATGCTGCCTTCTCT and TGTCTTCCCTGCTGTACTGT.
Online supplemental material
Fig. S1 shows time-course analysis of numbers of CD8 T cells (a), granzyme 
B expression by CD8 T cells (b), and accumulation of IFN-γ–expressing 
CD8 T cells (d), in the salivary glands of anti-OX40 or control IgG-treated 
mice. Panel c shows MCMV-specifi  c CD8 T cell accumulation in the 
  salivary glands at day 7 after infection in anti-OX40–treated or control IgG-
treated mice.
Fig. S2 shows the numbers of CD8+/IFN-γ+ and NK+/CD3−/IFN-γ+ 
cells (a) and the percentage (b) and the mean fl  uorescent intensity (c) of 
MHC class II expression by leukocytes in the salivary glands of anti–IL-10R 
or control IgG-treated mice 14 d after infection.
The authors wish to thank Dr. Kirsten Schneider and Professor Brigitte Askonas for 
valuable discussions; Xiaohong Tang, Yan Fei Adams, and Antje Rhodes for excellent 
technical support; Dr. Ann Hill for MCMV peptide sequences recognized by CD8 
T cells; and Dr. Tim Cheung for assistance with fi  gure preparation.
This work was supported in part by National Institutes of Health (NIH) grants 
CA91837 and AI67341 (to M. Croft); NIH Predoctoral Fellowship T32 AI060536 
(to A. Kinkade); and AI48073, AI057840, and R37AI33068 (to C.F. Ware). This is 
publication #793 from the La Jolla Institute for Allergy and Immunology.
The authors have no confl  icting fi  nancial interests.
Submitted: 17 November 2006
Accepted: 13 April 2007
REFERENCES
 1. Britt, W.J., and C.A. Alford. 1996. Cytomegalovirus. In Virology. 
B.N. Fields and D.M. Knipe, editors. Lippincott-Raven Publishers, 
Philadelphia, PA. 2493–2523.
 2. Zanghellini, F., S.B. Boppana, V.C. Emery, P.D. Griffi   ths, and R.F. 
Pass. 1999. Asymptomatic primary cytomegalovirus infection: virologic 
and immunologic features. J. Infect. Dis. 180:702–707.
 3. Rowe, W.P., J.W. Hartley, Cramblett, and F.M. Mastrota. 1958. 
Detection of human salivary gland virus in the mouth and urine of children. 
Am. J. Hyg. 67:57–65.
 4. Henson, D., and A.J. Strano. 1972. Mouse cytomegalovirus. Necrosis 
of infected and morphologically normal submaxillary gland acinar cells 
during termination of chronic infection. Am. J. Pathol. 68:183–202.
  5.  Jonjic, S., W. Mutter, F. Weiland, M.J. Reddehase, and U.H. Koszinowski. 
1989. Site-restricted persistent cytomegalovirus infection after selec-
tive long-term depletion of CD4+ T lymphocytes. J. Exp. Med. 169:
1199–1212.
 6. Bukowski, J.F., B.A. Woda, and R.M. Welsh. 1984. Pathogenesis of 
murine cytomegalovirus infection in natural killer cell-depleted mice. 
J. Virol. 52:119–128.
 7. Reddehase, M.J., M. Balthesen, M. Rapp, S. Jonjic, I. Pavic, and U.H. 
Koszinowski. 1994. The conditions of primary infection defi  ne the load 
of latent viral genome in organs and the risk of recurrent cytomegalo  virus 
disease. J. Exp. Med. 179:185–193.
  8.  Lucin, P., I. Pavic, B. Polic, S. Jonjic, and U.H. Koszinowski. 1992. 
Gamma interferon-dependent clearance of cytomegalovirus infection in 
salivary glands. J. Virol. 66:1977–1984.
 9. Heise, M.T., M. Connick, and H.W. Virgin IV. 1998. Murine cyto-
megalovirus inhibits interferon gamma-induced antigen presentation 
to CD4 T cells by macrophages via regulation of expression of ma-
jor histocompatibility complex class II–associated genes. J. Exp. Med. 
187:1037–1046. 
10.  Lu, X., A.K. Pinto, A.M. Kelly, K.S. Cho, and A.B. Hill. 2006. Murine 
cytomegalovirus interference with antigen presentation contributes to 
the inability of CD8 T cells to control virus in the salivary gland. J. Virol. 
80:4200–4202.1224  IL-10 AND OX40 COUNTERREGULATE ANTIVIRAL T CELLS | Humphreys et al.
11. Cavanaugh, V.J., Y. Deng, M.P. Birkenbach, J.S. Slater, and A.E. 
Campbell. 2003. Vigorous innate and virus-specifi  c cytotoxic T-lym-
phocyte responses to murine cytomegalovirus in the submaxillary sali-
vary gland. J. Virol. 77:1703–1717.
12. Mayer, L., and L. Shao. 2004. Therapeutic potential of oral tolerance. 
Nat. Rev. Immunol. 4:407–419.
13.  O’Garra, A., and P. Vieira. 2004. Regulatory T cells and mechanisms of 
immune system control. Nat. Med. 10:801–805.
14. Roncarolo, M.G., R. Bacchetta, C. Bordignon, S. Narula, and M.K. 
Levings. 2001. Type 1 T regulatory cells. Immunol. Rev. 182:68–79.
15.  Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to 
eff  ective T-cell immunity? Nat. Rev. Immunol. 3:609–620.
16.  Gramaglia, I., A. Jember, S.D. Pippig, A.D. Weinberg, N. Killeen, 
and M. Croft. 2000. The OX40 costimulatory receptor determines the 
  development of CD4 memory by regulating primary clonal expansion. 
J. Immunol. 165:3043–3050.
17. Rogers, P.R., and M. Croft. 2000. CD28, Ox-40, LFA-1, and CD4 
modulation of Th1/Th2 diff  erentiation is directly dependent on the 
dose of antigen. J. Immunol. 164:2955–2963.
18.  Ito, T., Y.H. Wang, O. Duramad, S. Hanabuchi, O.A. Perng, M. Gilliet, 
F.X. Qin, and Y.J. Liu. 2006. OX40 ligand shuts down IL-10-producing 
regulatory T cells. Proc. Natl. Acad. Sci. USA. 103:13138–13143.
19.  Ito, T., Y.H. Wang, O. Duramad, T. Hori, G.J. Delespesse, N. Watanabe, 
F.X. Qin, Z. Yao, W. Cao, and Y.J. Liu. 2005. TSLP-  activated den-
dritic cells induce an infl  ammatory T helper type 2 cell response through 
OX40 ligand. J. Exp. Med. 202:1213–1223.
20.  Humphreys, I.R., L. Edwards, G. Walzl, A.J. Rae, G. Dougan, S. Hill, 
and T. Hussell. 2003. OX40 ligation on activated T cells enhances the 
control of Cryptococcus neoformans and reduces pulmonary eosinophilia. 
J. Immunol. 170:6125–6132.
21.  So, T., J. Song, K. Sugie, A. Altman, and M. Croft. 2006. Signals from 
OX40 regulate nuclear factor of activated T cells c1 and T cell helper 
2 lineage commitment. Proc. Natl. Acad. Sci. USA. 103:3740–3745.
22.  Brooks, D.G., M.J. Trifi  lo, K.H. Edelmann, L. Teyton, D.B. McGavern, 
and M.B. Oldstone. 2006. Interleukin-10 determines viral clearance or 
persistence in vivo. Nat. Med. 12:1301–1309.
23. Ejrnaes, M., C.M. Filippi, M.M. Martinic, E.M. Ling, L.M. Togher, 
S. Crotty, and M.G. von Herrath. 2006. Resolution of a chronic   viral 
infection after interleukin-10 receptor blockade. J. Exp. Med. 203:
2461–2472.
24.  Sundstedt, A., I. Hoiden, A. Rosendahl, T. Kalland, N. van Rooijen, and 
M. Dohlsten. 1997. Immunoregulatory role of IL-10 during  superantigen-
induced hyporesponsiveness in vivo. J. Immunol. 158:180–186.
25. Sundstedt, A., E.J. O’Neill, K.S. Nicolson, and D.C. Wraith. 2003. 
Role for IL-10 in suppression mediated by peptide-induced regulatory 
T cells in vivo. J. Immunol. 170:1240–1248.
26.  Groux, H., A. O’Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. de 
Vries, and M.G. Roncarolo. 1997. A CD4+ T-cell subset   inhibits antigen-
specifi  c T-cell responses and prevents colitis. Nature. 389:737–742.
27.  Anderson, C.F., M. Oukka, V.J. Kuchroo, and D. Sacks. 2007. 
CD4+CD25−Foxp3− Th1 cells are the source of IL-10–mediated 
immune suppression in chronic cutaneous leishmaniasis. J. Exp. Med. 
204:285–297. 
28. Jankovic, D., M.C. Kullberg, C.G. Feng, R.S. Goldszmid, C.M. 
Collazo, M. Wilson, T.A. Wynn, M. Kamanaka, R.A. Flavell, and A. 
Sher. 2007. Conventional T-bet+Foxp3− Th1 cells are the major source of 
host-protective regulatory IL-10 during intracellular protozoan infection. 
J. Exp. Med. 204: 273–283.
29.  Moore, K.W., R.B. de Waal Malefyt, R.L. Coff  man, and A. O’Garra. 
2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 
19:683–765. 
30. Redpath, S., A. Angulo, N.R. Gascoigne, and P. Ghazal. 1999. 
Murine cytomegalovirus infection down-regulates MHC class II ex-
pression on macrophages by induction of IL-10. J. Immunol. 162:
6701–6707.
31. Shoemaker, J., M. Saraiva, and A. O’Garra. 2006. GATA-3 directly 
remodels the IL-10 locus independently of IL-4 in CD4+ T cells. 
J. Immunol. 176:3470–3479.
32.  Kopf, M., C. Ruedl, N. Schmitz, A. Gallimore, K. Lefrang, B. Ecabert, B. 
Odermatt, and M.F. Bachmann. 1999. OX40-defi  cient mice are defective 
in Th cell proliferation but are competent in generating B cell and CTL 
responses after virus infection. Immunity. 11:699–708.
33.  Humphreys, I.R., G. Walzl, L. Edwards, A. Rae, S. Hill, and T. Hussell. 
2003. A critical role for OX40 in T cell–mediated immunopathology 
during lung viral infection. J. Exp. Med. 198:1237–1242.
34.  Sher, A., and R.L. Coff  man. 1992. Regulation of immunity to parasites by 
T cells and T cell-derived cytokines. Annu. Rev. Immunol. 10:385–409.
35.  Presti, R.M., J.L. Pollack, A.J. Dal Canto, A.K. O’Guin, and H.W Virgin, 
4th. 1998. Interferon gamma regulates acute and lethal murine cyto-
megalovirus infection and chronic disease of the great vessels. J. Exp. 
Med. 188:577–588. 
36.  Lucin, P., S. Jonjic, M. Messerle, B. Polic, H. Hengel, and U.H. 
Koszinowski. 1994. Late phase inhibition of murine cytomegalovirus 
replication by synergistic action of interferon-gamma and tumour necrosis 
factor. J. Gen. Virol. 75:101–110.
37.  Gribaudo, G., S. Ravaglia, A. Caliendo, R. Cavallo, M. Gariglio, M.G. 
Martinotti, and S. Landolfo. 1993. Interferons inhibit onset of murine cyto-
megalovirus immediate-early gene transcription. Virology. 197:303–311.
38.  Weigent, D.A., G.J. Stanton, and H.M. Johnson. 1983. Interleukin 2 en-
hances natural killer cell activity through induction of gamma interferon. 
Infect. Immun. 41:992–997.
39. Heise, M.T., and H.W.t. Virgin. 1995. The T-cell-independent role 
of gamma interferon and tumor necrosis factor alpha in macrophage 
activation during murine cytomegalovirus and herpes simplex virus 
infections. J.Virol. 69:904–909. 
40.  Noda, S., K. Tanaka, S. Sawamura, M. Sasaki, T. Matsumoto, K. Mikami, 
Y. Aiba, H. Hasegawa, N. Kawabe, and Y. Koga. 2001. Role of nitric 
oxide synthase type 2 in acute infection with murine cytomegalovirus. 
J. Immunol. 166:3533–3541.
41. Benedict, C.A., C. De Trez, K. Schneider, S. Ha, G. Patterson, and 
C.F. Ware. 2006. Specifi  c remodeling of splenic architecture by cyto-
megalovirus. PLoS Pathog. 2:e16. 
42. Boname, J.M., and J.K. Chantler. 1992. Characterization of a strain of 
murine cytomegalovirus which fails to grow in the salivary glands of 
mice. J. Gen. Virol. 73:2021–2029.
43.  Tam, A., J. Zhu, R. Hai, E. Haghjoo, T. Tong, X. Zhan, S. Lu, and F. 
Liu. 2003. Murine cytomegalovirus with a transposon insertional muta-
tion at open reading frame M35 is defective in growth in vivo. J. Virol. 
77:7746–7755.
44.  Manning, W.C., C.A. Stoddart, L.A. Lagenaur, G.B. Abenes, and E.S. 
Mocarski. 1992. Cytomegalovirus determinant of replication in salivary 
glands. J. Virol. 66:3794–3802.
45. Lagenaur, L.A., W.C. Manning, J. Vieira, C.L. Martens, and E.S. 
Mocarski. 1994. Structure and function of the murine cytomegalovirus 
sgg1 gene: a determinant of viral growth in salivary gland acinar cells. 
J. Virol. 68:7717–7727.
46. Kotenko, S.V., S. Saccani, L.S. Izotova, O.V. Mirochnitchenko, and 
S. Pestka. 2000. Human cytomegalovirus harbors its own unique IL-10 
homolog (cmvIL-10). Proc. Natl. Acad. Sci. USA. 97:1695–1700.
47. Lockridge, K.M., S.S. Zhou, R.H. Kravitz, J.L. Johnson, E.T. Sawai, 
E.L. Blewett, and P.A. Barry. 2000. Primate cytomegaloviruses encode 
and express an IL-10-like protein. Virology. 268:272–280.
48. Hsu, D.H., R. de Waal Malefyt, D.F. Fiorentino, M.N. Dang, P. 
Vieira, J. de Vries, H. Spits, T.R. Mosmann, and K.W. Moore. 1990. 
Expression of interleukin-10 activity by Epstein-Barr virus protein 
BCRF1. Science. 250:830–832.
49. Rode, H.J., W. Janssen, A. Rosen-Wolff  , J.J. Bugert, P. Thein, Y. 
Becker, and G. Darai. 1993. The genome of equine herpesvirus type 2 
harbors an interleukin 10 (IL10)-like gene. Virus Genes. 7:111–116.
50. Grusby, M.J., R.S. Johnson, V.E. Papaioannou, and L.H. Glimcher. 
1991. Depletion of CD4+ T cells in major histocompatibility complex 
class II-defi  cient mice. Science. 253:1417–1420.
51.  Reddehase, M.J., F. Weiland, K. Munch, S. Jonjic, A. Luske, and U.H. 
Koszinowski. 1985. Interstitial murine cytomegalovirus pneumonia af-
ter irradiation: characterization of cells that limit viral replication during 
established infection of the lungs. J. Virol. 55:264–273.JEM VOL. 204, May 14, 2007  1225
ARTICLE
52.  Al Shamkhani, A., M.L. Birkeland, M. Puklavec, M.H. Brown, W. James, 
and A.N. Barclay. 1996. OX40 is diff  erentially expressed on activated rat 
and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. 
Immunol. 26:1695–1699.
53. O’Farrell, A.M., Y. Liu, K.W. Moore, and A.L. Mui. 1998. IL-10 
inhibits macrophage activation and proliferation by distinct signaling 
mechanisms: evidence for Stat3-dependent and -independent pathways. 
EMBO J. 17:1006–1018.
54.  Munks, M.W., M.C. Gold, A.L. Zajac, C.M. Doom, C.S. Morello, D.H. 
Spector, and A.B. Hill. 2006. Genome-wide analysis reveals a highly 
diverse CD8 T cell response to murine cytomegalovirus. J. Immunol. 
176:3760–3766.
55. Benedict, C.A., T.A. Banks, L. Senderowicz, M. Ko, W.J. Britt, A. 
Angulo, P. Ghazal, and C.F. Ware. 2001. Lymphotoxins and cyto-
megalovirus cooperatively induce interferon-β, establishing host-virus 
détente. Immunity. 15:617–626.